8-K - Aptose Biosciences Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Aptose Biosciences announced that Institutional Shareholder Services (ISS) recommends shareholders vote 'FOR' the Arrangement Resolution approving Hanmi Pharmaceutical's acquisition of all outstanding common shares not owned by Hanmi affiliates at C$2.41 per share, a 28% premium to the 30-day TSX VWAP of C$1.88. ISS also supports the Continuance to Alberta's Business Corporations Act ahead of the reconvened shareholder meeting on March 31, 2026.

Key Takeaways

1ISS recommends 'FOR' Arrangement Resolution for Hanmi acquisition of Aptose common shares

2Cash consideration of C$2.41 per common share, 28% premium to 30-day TSX VWAP of C$1.88

3ISS recommends 'FOR' Continuance from CBCA to ABCA with no adverse impact on shareholder rights

4Reconvened shareholder meeting on March 31, 2026 at 11:00 a.m. EST via live audio webcast

5Proxy voting deadline of March 27, 2026 at 11:00 a.m. Eastern time

6Aptose board unanimously recommends voting 'FOR' both resolutions

Current Report Details

Event Type

Regulation Fd

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

. Regulation FD Disclosure. On March 19, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated her

Regulation Fd

9.01

. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated March 19, 2026 104 Cover Page Interactive Data File (embed

Exhibits Only

Source Document

Transaction Details

Acquisition / Disposition

Target: Aptose Biosciences Inc. common shares
Consideration: C$2.41 in cash per common share
Structure: Plan of Arrangement

•Reconvened shareholder meeting on 2026-03-31
•Interim order from Court of King’s Bench of Alberta
•Approval of TSX
•Customary closing conditions

Exhibits (2)

8-K

FORM 8-K

99.1

PRESS RELEASE